Cargando…

Increasing Role of Targeted Immunotherapies in the Treatment of AML

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The standard of care in medically and physically fit patients is intensive induction therapy. The majority of these intensively treated patients achieve a complete remission. However, a high number of these patients will exper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greiner, Jochen, Götz, Marlies, Wais, Verena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953556/ https://www.ncbi.nlm.nih.gov/pubmed/35328721 http://dx.doi.org/10.3390/ijms23063304

Ejemplares similares

Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients
por: Greiner, Jochen, et al.
Publicado: (2019)

Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma
por: Zhang, Lu, et al.
Publicado: (2012)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

The Important Role of Immunotherapies in Acute Myeloid Leukemia
por: Greiner, Jochen
Publicado: (2019)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Rational Combinations of Targeted Agents in AML
por: Bose, Prithviraj, et al.
Publicado: (2015)

P477: COMBINATION OF DIFFERENT IMMUNOTHERAPEUTIC DRUGS ENHANCES SPECIFIC T CELL IMMUNE RESPONSES AGAINST LEUKEMIC CELLS AND LEUKEMIC PROGENITOR/STEM CELLS IN ACUTE MYELOID LEUKEMIA
por: Greiner, Jochen, et al.
Publicado: (2023)

Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy
por: Puntigam, Lisa K., et al.
Publicado: (2020)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel
por: Viardot, Andreas, et al.
Publicado: (2019)

Catch me if you can: how AML and its niche escape immunotherapy
por: Tettamanti, Sarah, et al.
Publicado: (2021)

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

Treatments for children and adolescents with AML
por: Kim, Hyery
Publicado: (2020)

Optical Genome Mapping for Cytogenetic Diagnostics in AML
por: Nilius-Eliliwi, Verena, et al.
Publicado: (2023)

Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions
por: Engen, Caroline Benedicte Nitter, et al.
Publicado: (2014)

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
por: Halik, Adriane, et al.
Publicado: (2022)

Targeting Apoptosis in AML: Where Do We Stand?
por: Krawiec, Kinga, et al.
Publicado: (2022)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
por: Ruzicka, Michael, et al.
Publicado: (2019)

Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)
por: Cao, Ziyang, et al.
Publicado: (2022)

Combination Therapies Targeting Apoptosis in Paediatric AML: Understanding the Molecular Mechanisms of AML Treatments Using Phosphoproteomics
por: Ali, Ahlam A., et al.
Publicado: (2023)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Targeting glutamine uptake in AML
por: Jacque, Nathalie, et al.
Publicado: (2014)

The Time Has Come for Targeted Therapies for AML: Lights and Shadows
por: Fiorentini, Alessandro, et al.
Publicado: (2020)

Targeting Leukemia Stem Cell-Niche Dynamics: A New Challenge in AML Treatment
por: Bernasconi, Paolo, et al.
Publicado: (2019)

Progress toward Better Treatment of Therapy-Related AML
por: Kotsiafti, Angeliki, et al.
Publicado: (2023)

Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment
por: Banella, Cristina, et al.
Publicado: (2022)

BRD4: A BET(ter) target for the treatment of AML?
por: Valent, Peter, et al.
Publicado: (2014)

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
por: Chen, Jing, et al.
Publicado: (2020)

Update of ALDH as a Potential Biomarker and Therapeutic Target for AML
por: Yang, Xiangchou, et al.
Publicado: (2018)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Precision medicine in the treatment stratification of AML patients: challenges and progress
por: Lohse, Ines, et al.
Publicado: (2018)

AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances
por: Koenig, Kristin L., et al.
Publicado: (2020)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

AML treatment in older adults
por: Sehgal, Alison, et al.
Publicado: (2015)

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
por: Winer, Eric S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u5ega5rkr1c2laea8prvfgeqr2